Here is the latest stock price and chart of JAGSON PHAR. For more details, see the JAGSON PHAR company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Today at 5 PM: Top 3 Stocks for 2022 Revealed
Live BSE Quotes | May 24, 2022 10:54:00 AM | ||
---|---|---|---|
Price (Rs)308.00 | Open (Rs) 310.00 | High (Rs) 313.40 | Low (Rs) 305.60 |
% Change-0.63 | Volume 1,706 | Value (Rs) 525,448 | 52-Week H/L 369.55 / 96.35 |
Live NSE Quotes | May 24, 2022 10:59:52 AM | ||
---|---|---|---|
Price (Rs)310.65 | Open (Rs) 317.50 | High (Rs) 317.50 | Low (Rs) 305.05 |
% Change-0.02 | Volume 12,171 | Value (Rs) 3,764,977 | 52-Week H/L 369.00 / 96.20 |
Change | |||||
---|---|---|---|---|---|
1 Day -0.63% | 1 Month 1.95% | 3 Months 29.06% | 1 Year 212.06% | 5 Years (CAGR)* 51.73% | 10 Years (CAGR)* 37.15% |
* Compound Annual Growth Rate
Valuation | ||||
---|---|---|---|---|
EPS (Rs)* 9.41 | P/E Ratio (x) 32.72 | Market Cap (Rs m) 8,068.98 | P/BV (x) 6.62 | Dividend Yield (%) 0.00 |
*Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
![]() |
||
S&P BSE SENSEX ![]() |
||||||
PERIOD |
JAGSON PHAR last traded price was down 0.6% to Rs 308.0 on the BSE. On the NSE, JAGSON PHAR last traded price was down 0.0% to Rs 310.7. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.8%. And the benchmark S&P BSE SENSEX was at 54,179.7 (down 0.2%).
Over the last 30 days, the JAGSON PHAR share price is down 5.2%. And over the last one year, JAGSON PHAR share price is up 217.5%.
The current market capitalisation of JAGSON PHAR stands at Rs 8,068.98 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of March 2022, company promoters held 68.71% stake in JAGSON PHAR, with no shares having been pledged. To know more, check out the latest shareholding pattern of JAGSON PHAR.
What else is happening in the markets today? Dig in...
Asian share markets are lower today as relief rally hopes on Wall Street quickly soured by a slide in US stock futures.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.
The strong momentum in India's IPO market is poised to continue with the market regulator approving the IPOs of three firms including PharmEasy.
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More